Vous avez cherché: kombinatsioonravil (Estonien - Anglais)

hüpoglükeemia (kombinatsioonravil ainult metformiiniga)
hypoglycaemia (in combination with metformin alone)

40 patsiendi kombinatsioonravil dotsetakseeli ja tsisplatiiniga.
406 patients who received docetaxel in combination with cisplatin.

92 patsiendi kombinatsioonravil dotsetakseeli ja trastusumaabiga;
92 patients treated with docetaxel in combination with trastuzumab.

- 255 patsiendi kombinatsioonravil dotsetakseeli ja kapetsitabiiniga.
no studies on the effects on the ability to drive and use machines have been performed.

- 744 patsiendi kombinatsioonravil dotsetakseeli, doksorubitsiini ja tsüklofosfamiidiga (esitatud
the adverse reactions considered to be possibly or probably related to the administration of docetaxel have been obtained in: • 1312 and 121 patients who received 100 mg/ m² and 75 mg/ m² of docetaxel as a single agent respectively. • 258 patients who received docetaxel in combination with doxorubicin. • 406 patients who received docetaxel in combination with cisplatin. • 92 patients treated with docetaxel in combination with trastuzumab.

kliiniliste uuringute andmed on näidanud, et raas-i kahekordne blokaad kombinatsioonravil
clinical trial data has shown that dual blockade of the raas through the combined use of

kombinatsioonravil põhinevat viljatusravi saanud naistel on täheldatud munasarjade ning teiste suguorganite hea - ja pahaloomulisi kasvajaid.
95 there have been reports of ovarian and other reproductive system neoplasms, both benign and malignant, in women who have undergone multiple drug regimens for infertility treatment.

332 patsiendi kombinatsioonravil dotsetakseeli ja prednisooni või prednisolooniga (esitatud on kliiniliselt olulised raviga seotud kõrvalnähud);
332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented).

uuringu ii faasi osas) kombinatsioonravil dotsetakseeli, tsisplatiini ja 5– fluorouratsiiliga (esitatud on kliinilist tähtsust omavad raviga seotud kõrvaltoimed).
45 • 92 patients treated with docetaxel in combination with trastuzumab. • 255 patients who received docetaxel in combination with capecitabine. • 332 patients who received docetaxel in combination with prednisone or prednisolone (clinically important treatment related adverse events are presented). • 744 patients who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented). • 300 gastric adenocarcinoma patients (221 patients in the phase iii part of the study and 79 patients in the phase ii part) who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented). • 174 and 251 head and neck cancer patients who received docetaxel in combination with cisplatin and 5-fluorouracil (clinically important treatment related adverse events are presented).

1276 patsiendi (744 patsienti uuringus tax 316 ja 316 patsienti uuringus geicam 9805) kombinatsioonravil dotsetakseeli, doksorubitsiini ja tsüklofosfamiidiga (esitatud on andmed kliiniliselt oluliste raviga seotud kõrvalnähtude kohta)
1276 patients (744 and 532 in tax 316 and geicam 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).